Clinical Trials Directory

Trials / Completed

CompletedNCT06535204

Effects of Anthriscus Sylvestris Leaves on Mild Knee Osteoarthritis

Effects of Oral Administration of Anthriscus Sylvestris Leaves on Mild Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
100 (actual)
Sponsor
Pusan National University Hospital · Academic / Other
Sex
All
Age
40 Years – 75 Years
Healthy volunteers
Accepted

Summary

Osteoarthritis (OA) is a common degenerative joint disorder that causes pain, stiffness, and functional impairment. Current treatments for OA are limited to symptom relief and have potential side effects. Anthriscus sylvestris leaves are a natural remedy that has been shown to have anti-inflammatory and cartilage-protective effects in animal models of OA.

Detailed description

Osteoarthritis (OA) is a common degenerative joint disorder that causes pain, stiffness, and functional impairment. Current treatments for OA are limited to symptom relief and have potential side effects. Anthriscus sylvestris leaves are a natural remedy that has been shown to have anti-inflammatory and cartilage-protective effects in animal models of OA. A randomized, double-blind, placebo-controlled trial was conducted with 100 participants aged 40 to 75 with Kellgren \& Lawrence grade 1 or 2 knee OA. Participants were assigned to receive either 500 mg of Anthriscus sylvestris leaves extract or placebo daily for 12 weeks. The primary outcome was the change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score from baseline to week 12. Secondary outcomes included the changes in visual analogue scale (VAS) for pain, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) from baseline to week 12. The Anthriscus sylvestris leaves extract group showed a significant improvement in the total WOMAC score, as well as the pain, stiffness, and physical function sub-scores, compared with the placebo group after 12 weeks of treatment. The Anthriscus sylvestris leaves extract group also showed a significant reduction in VAS and CRP, but not in ESR, compared with the placebo group. No adverse events or safety concerns were reported in either group. Anthriscus sylvestris leaves extract enhanced joint and cartilage health in humans with mild OA symptoms, as indicated by the reduction in WOMAC, VAS, and CRP. The extract was also safe and well-tolerated. Anthriscus sylvestris leaves extract may be a promising natural alternative for the management and prevention of OA.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTAqueous extract of A. sylvestris leavesProvided functional food made from Aqueous extract of A. sylvestris leaves
DIETARY_SUPPLEMENTmicrocrystalline celluloseProvided placebo composed of microcrystalline cellulose instead of A. sylvestris leaf extract.

Timeline

Start date
2019-06-24
Primary completion
2020-04-30
Completion
2020-04-30
First posted
2024-08-02
Last updated
2024-08-02

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT06535204. Inclusion in this directory is not an endorsement.